Jamie Finlay
banner
jamiefinlay.bsky.social
Jamie Finlay
@jamiefinlay.bsky.social
He/Him. Heart Failure Nurse interested in Education, Emerging Technologies & Cardiac Rehab
Reposted by Jamie Finlay
Nick Hartshorne-Evans the Founder and CEO of the Pumping Marvellous Foundation, the UK’s heart failure charity based in Preston, has been named in the New Year’s Honours list. Read more here pumpingmarvellous.org/new-year-honou…#NewYearsHonoursrs
https://pumpingmarvellous.org/new-year-honou…
December 31, 2024 at 10:16 AM
Great discussion from an amazing panel regarding #weightloss #obesity #BSHAM2024
November 22, 2024 at 11:17 AM
Some great advice from the #dieticians regarding obesity and helping patients lose weight 🏃🥗👂#BSHAM2024
November 22, 2024 at 10:12 AM
Last up today at the #BSHAM2024 🫀vs🫘 - I know who I have my money on (not biased as a cardiology nurse🤣)
November 21, 2024 at 5:08 PM
Huge Congratulations to the Aneurin Bevan Health boards #heartfailure #consultantnurse Linda Edmunds MBE for her nomination of the #lindabloomaward at the #BSHAM2024.
Thanks to Gwent #cardicrehab their support 💚
November 21, 2024 at 12:06 PM
Ready for the #BSHAM2024 -
Our #heartfailure Posters are up from the #ABUHB in #wales … and I have had coffee
November 21, 2024 at 9:13 AM
Down in London for the #bsh2024; ready for 2 days of #heartfailure related learning🫀
November 20, 2024 at 8:19 PM
Reposted by Jamie Finlay
Another GLP-1 drug success. Tirzepatide in heart failure with preserved ejection fraction (HFpEF) with longer term follow-up than 2 previous trials with semaglutide
nejm.org/doi/full/10....
in people with BMI >30; no data yet for HFpEF in people without obesity
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | NEJM
Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor...
nejm.org
November 16, 2024 at 3:12 PM